BioMatrix Specialty Pharmacy Statement on Specialty Drug Availability
The following is a statement provided by BioMatrix. “BioMatrix Specialty Pharmacy is closely monitoring the COVID-19 pandemic. Our organization has initiated proper response measures to ensure bleeding disorder patients maintain access to the specialty drugs required to effectively manage their condition throughout this emergent situation. BioMatrix is leveraging its national footprint, detailed business continuity plans, and extensive assets […]
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
The following is information provided by Pfizer and BioNTech.On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to collaboration to combat COVID-19. Â Pfizer Inc. and BioNTech announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) […]
IXINITY Statement on Product Availability
The following is information provided by IXINITY. Read the full statement here. “The health and safety of individuals who rely on our products, their caregivers and community members, healthcare professionals, and our own team is of upmost importance to Medexus Pharma, the company behind IXINITY. We want to reassure the community that we currently do […]
Plasma Protein Therapeutics Association Updated Statement Regarding Coronavirus
The following is a statement provided by PPTA. “Hello Stakeholders, As previously noted, I am writing to inform you of an update to PPTA’s statement regarding coronavirus and the safety of plasma protein therapies. This update provides clarity regarding the safety margins of plasma protein therapies manufactured by PPTA member companies and maintains the main assessment of […]
Grifols Update Regarding the Novel Coronavirus
The following is a statement provided by Grifols. “As the situation with the novel coronavirus rapidly evolves, we wanted to inform you that Grifols is taking measures in line with recommendations from the World Health Organization (WHO) to help ensure the safety of our employees, donors, products, and the patient communities we serve. We have […]
Novo Nordisk Pauses Clinical Trials Investigating Concizumab
The following is an excerpt from a press release published by Novo Nordisk. Novo Nordisk announced that two clinical trials in the concizumab phase 3 programme (explorer7 and 8) and one clinical trial in the phase 2 programme (explorer5) have been paused. The three clinical trials were investigating concizumab prophylaxis treatment in haemophilia A and […]
Sanofi Looks to Leverage Previous SARS Vaccine Information to Develop COVID-19 Vaccine
The following is a response provided by Sanofi. “At Sanofi, we have a simple purpose – to discover breakthrough medicines and vaccines to improve the lives of millions of people around the world. This drive to transform the practice of medicine has taken on increased urgency for everyone in the Sanofi family since the emergence […]
Novo Nordisk Letter to the Bleeding Disorders Community on COVID-19
The following is a letter provided by Novo Nordisk.  “You’ve come to know us as a part of the fabric of the hemophilia community for more than 30 years, always working to make things better for everyone affected by rare bleeding disorders. We know this is a challenging time for all as with the World Health […]
CSL Behring Update COVID-19
CSL Behring has added a statement to their website regarding the measures the company is taking in the wake of the 2019-nCoV (novel coronavirus) outbreak.
VONVENDI Recall – Takeda Response
As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U. vials on Feb. 25, 2020. HFA and NHF recognize that recalls can be very unsettling for many in the bleeding disorders community. On Feb. 27, 2020, the patient organizations announced they had submitted a […]
English 
Español de Puerto Rico